(Q38481449)

3 September 2017

title

Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study (English)

1 reference

multicenter clinical trial

3 September 2017

main subject

0 references

World Health Organization

0 references

Adaptive radiation therapy

0 references

Chul-Kee Park

2

0 references

author name string

Young-Hoon Kim

1

1 reference

3 September 2017

Won Ho Cho

3

1 reference

3 September 2017

In Ah Kim

4

1 reference

3 September 2017

Seyoung Moon

5

1 reference

3 September 2017

Gheeyoung Choe

6

1 reference

3 September 2017

Sung-Hye Park

7

1 reference

3 September 2017

Il Han Kim

8

1 reference

3 September 2017

Dong Gyu Kim

9

1 reference

3 September 2017

Hee-Won Jung

10

1 reference

3 September 2017

Min Mi Lee

11

1 reference

3 September 2017

So Hyun Bae

12

1 reference

3 September 2017

Seung Heon Cha

13

1 reference

3 September 2017

Chae-Yong Kim

14

1 reference

3 September 2017

language of work or name

1 reference

24 September 2010

1 reference

Journal of Neuro-Oncology

3 September 2017

published in

1 reference

3 September 2017

volume

103

1 reference

3 September 2017

issue

3

1 reference

3 September 2017

page(s)

503-512

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-010-0404-5

3 September 2017

exact match

0 references

cites work

Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

The WHO classification of tumors of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Long-term survival with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Diagnosis and treatment of high-grade astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Chemoradiotherapy in malignant glioma: standard of care and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Successful chemotherapy for recurrent malignant oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0404-5

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

21 January 2018

1 reference

12 December 2020

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

12 December 2020

1 reference

12 December 2020

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Adjuvant chemotherapy for adults with malignant glioma: a systematic review

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

10.1007/S11060-010-0404-5

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1015379409

0 references

1 reference